Michael Dore
LOWENSTEIN SANDLER LLP
65 Livingston Avenue
Roseland, New Jersey 07068
(973) 597-2500
NJ License No. 034581980
Attorney for Defendants Warner Chilcott (US), LLC, as
Successor in interest to Procter & Gamble Pharmaceuticals
Inc., sanofi-aventis U.S. L.L.C., and Sanofi US Services Inc.

FILED SEP 3 0 2015

JUDGE JESSICA R. MAYER

IN THE SUPERIOR COURT OF NEW JERSEY LAW DIVISION, MIDDLESEX COUNTY

AUDREY R. COMPORT,	X	
,	:	
	:	
	:	
Plaintiff,	:	
	:	
	:	
	:	
vs.	:	Civil Action No.: MID-L-8576-14
	:	Fosamax Litigation (Case No. 282)
MERCK SHARP & DOHME, CORP.;	:	
TEVA PHARMACEUTICALS USA, INC.;	:	STIPULATION AND ORDER OF
SANOFI-AVENTIS U.S. INC.; SANOFI-	:	DISMISSAL WITH PREJUDICE
AVENTIS U.S. LLC; WARNER	:	
CHILCOTT PHARMACEUTICALS INC.;	:	
and PROCTER & GAMBLE	:	
PHARMACEUTICALS, INC.	:	
	:	
	:	
Defendants	:	
Defendants.		
	X	

IT IS HEREBY STIPULATED AND AGREED by and between Plaintiff Audrey R. Comport ("Plaintiff") and Defendant Warner Chilcott (US), LLC ("Warner Chilcott"), through their respective undersigned counsel, that all of Plaintiff's claims against sanofi-aventis U.S.

Inc., sanofi-aventis U.S. L.L.C.¹, Warner Chilcott Pharmaceuticals Inc., and Procter & Gamble Pharmaceuticals, Inc.² are hereby dismissed with prejudice pursuant to Rule 4:37-1(a) of the New Jersey Rules of Court. Each party will bear its own costs and fees.

Plaintiff's claims against Defendants Merck & Co., Inc. and Teva Pharmaceuticals USA, Inc. are not dismissed by this Stipulation of Dismissal and remain pending.

DATED:

28/15,2015.

The Levensten Law Firm PC

1420 Walnut Street

Suite 1500

Philadelphia, PA 19102

(215) 545-5600

Attorneys for Plaintiff

By:

Michael Dore

Lowenstein Sandler LLP

65 Livingston Avenue Roseland, NJ 07068

(973) 597-2500

Lana K. Varney

Norton Rose Fulbright US LLP

98 San Jacinto Blvd.

Suite 1100

Austin, TX 78701

(512) 474-5201

Attorneys for Defendants

Warner Chilcott (US), LLC, sanofi-aventis U.S. L.L.C., and Sanofi US Services Inc.

¹ sanofi-aventis U.S. L.L.C. is the successor in interest to Aventis Pharmaceuticals, Inc. sanofi-aventis U.S. L.L.C. co-promoted Actonel® with Procter & Gamble Pharmaceuticals, Inc. until October 30, 2009, after which it copromoted Actonel® with Warner Chilcott Pharmaceuticals Inc. until April 1, 2010. On April 1, 2010, sanofi-aventis U.S. L.L.C. ceased its co-promotion of Actonel®, and Warner-Chilcott Pharmaceuticals Inc. assumed full responsibility for the promotion of Actonel®.

² On February 1, 2010, Procter & Gamble Pharmaceuticals, Inc. became known as Warner Chilcott Pharmaceuticals Inc. In connection with that name change, Warner Chilcott Pharmaceuticals Inc. served as the successor in interest to Procter & Gamble Pharmaceuticals, Inc. Effective as of January 1, 2011, Warner Chilcott Pharmaceuticals Inc. was merged into Warner Chilcott (US), LLC, and no longer exists as a distinct entity. In connection with this transaction, Warner Chilcott (US), LLC now serves as the successor in interest to Procter & Gamble Pharmaceuticals, Inc.

By: Willer Wisher		
Eileen Oakes Muskett		
Fox Rothschild LLP		
Midtown Building		
1301 Atlantic Avenue		
Suite 400		
Atlantic City, NJ 08401		

Attorneys for Defendant Merck Sharp & Dohme, Corp.

Goodwin Procter LLP	
New York Times Building	
620 Eight Avenue	
New York, NY 01018	

SO ORDERED:

Honorable Jessica R. Mayer, J.S.C.

DATED:

, 2015

	By:
	Eileen Oakes Muskett
	Fox Rothschild LLP
	Midtown Building
	1301 Atlantic Avenue
	Suite 400
	Atlantic City, NJ 08401
	Attorneys for Defendant
	Merck Sharp & Dohme, Corp.
	By: Kate Seib
	Kate D. Seib
	Goodwin Procter LLP
	New York Times Building
	620 Eight Avenue
	New York, NY 01018
	Attorneys for Defendant
	Teva Pharmaceuticals USA, Inc.
SO ORDERED: Hor	norable Jessica R. Mayer, J.S.C.
DATED:	, 2015